262 related articles for article (PubMed ID: 33113601)
21. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
23. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN
Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939
[TBL] [Abstract][Full Text] [Related]
24. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
25. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():858590. PubMed ID: 35371098
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
27. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Jiang H; Hu Y; Mei H
Biomark Res; 2020 Nov; 8(1):66. PubMed ID: 33292685
[TBL] [Abstract][Full Text] [Related]
28. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y
Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277
[TBL] [Abstract][Full Text] [Related]
29. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].
Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
32. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results.
Li Z; Yang K; Song Y; Zhao Y; Wu F; Wen X; Li J; Wang X; Xu T; Zheng X; Zheng Q; Wu T
Front Oncol; 2022; 12():1048296. PubMed ID: 36686744
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
Chen M; Fu M; Wang A; Wu X; Zhen J; Gong M; Zhang X; Yue G; Du Q; Zhao W; Zhao Y; Lu P; Wang H
Leuk Lymphoma; 2022 Feb; 63(2):426-434. PubMed ID: 34672246
[TBL] [Abstract][Full Text] [Related]
34. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
Front Immunol; 2022; 13():934442. PubMed ID: 36110859
[TBL] [Abstract][Full Text] [Related]
35. [Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia].
Su Y; Bao S; Wei YP; Song LJ; Xue YM; Wei XD; Song YP; Yin QS
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):946-951. PubMed ID: 36709187
[No Abstract] [Full Text] [Related]
36. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
Li N; Li H
J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
[TBL] [Abstract][Full Text] [Related]
37. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
38. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.
Xu Q; Shi Y; Xue L; An F; Xu H; Liu X; Zhu X; Sun Z; Zhai Z; Wang X
Cell Transplant; 2023; 32():9636897231204724. PubMed ID: 37846503
[TBL] [Abstract][Full Text] [Related]
40. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]